Friday, September 26, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Medicine

Insilico Medicine introduces Science42: DORA, the intelligent writing assistant for accelerated research

July 26, 2024
in Medicine
Reading Time: 4 mins read
0
Insilico Medicine Introduces Science42: DORA, the Intelligent Writing Assistant for Accelerated Research
65
SHARES
595
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

Writing research papers is critical for disseminating scientific findings, but it does come with efficiency burdens, particularly for early-career researchers and non-native English speakers. A survey published in Nature in 2018 indicated that approximately 37% of respondents reported that they spend more than 20 hours a week on writing and revising scientific papers.

Insilico Medicine Introduces Science42: DORA, the Intelligent Writing Assistant for Accelerated Research

Credit: Insilico Medicine

Writing research papers is critical for disseminating scientific findings, but it does come with efficiency burdens, particularly for early-career researchers and non-native English speakers. A survey published in Nature in 2018 indicated that approximately 37% of respondents reported that they spend more than 20 hours a week on writing and revising scientific papers.

Recent progress in Natural Language Processing (NLP) technology, particularly with the rise of Generative Pre-trained Transformers (GPT) and other Large Language Models (LLMs), has equipped researchers with a powerful set of tools for processing extensive amounts of literature quickly. Insilico Medicine (“Insilico”), a clinical-stage generative AI-driven biotechnology company, has launched a preview version of its draft outline research assistant, Science42:DORA, to streamline the generation of scientific content.

Science42: DORA (aka DORA) integrates multiple AI agents that leverage LLMs, designed to streamline the process of drafting academic papers and other scientific documents including grant and patent applications, internal research summaries, IND applications, etc. It assists researchers in drafting these types of documents with proper referencing through engineered prompts, proprietary databases, and pre-designed content generation workflows. 

“Often the most difficult step when it comes to writing is starting the process. Something that I experienced first-hand as a graduate student when I was tasked with writing numerous grants, papers and reports.” said Petrina Kamya, PhD, Global head of AI Platform, Vice President of Insilico Medicine. “We developed Science42:DORA to help eliminate that debilitating barrier to writing scientific documents.”

To further validate DORA’s abilities, Insilico’s developers collaborated with researchers at the University of Copenhagen to submit a paper on medRxiv. The paper drafted by DORA and later manually curated and extended, performs a comparative study about radiotherapy outcomes across brain tumor types, namely Glioblastoma Multiform and Low-Grade Gliomas based on radiotherapy phenotype and expression data from 32 cancer datasets. Insilico plans to further test DORA in multiple types of document generation and launch a free trial version of the AI assistant to the public in late 2024.

“Here at Insilico, we strive to integrate state-of-art AI innovations with human intelligence for faster and better advancements in research and development, and LLM-based AI agents have been our recent focus.” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “With DORA, we hope not only to streamline the writing process but also to elevate the overall quality of scholarly output, which in turn powers practical applications and meaningful delivery.”

Insilico Medicine is a pioneer in using generative AI for drug discovery and development. The Company first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016. Then, Insilico developed and validated multiple approaches and features for its generative adversarial network (GAN)-based AI platform and integrated those algorithms into the commercially available Pharma.AI platform, which includes generative biology, chemistry, and medicine.

Since 2021, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 promising therapeutic assets and has advanced seven molecules to the clinical stage. In March 2024, the Company published a paper in Nature Biotechnology that discloses the raw experimental data and the preclinical and clinical evaluation of its lead drug – a potentially first-in-class TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis discovered and designed using generative AI currently in Phase II trials with patients. 

 

About Insilico Medicine

Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and generating novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com



Share26Tweet16
Previous Post

Determining maximum allowable current of an RBS using a directed graph model and greedy algorithm

Next Post

Fresh light on the path to net zero

Related Posts

blank
Medicine

Addressing Racial and Ethnic Disparities in Occupational Health

September 26, 2025
blank
Medicine

Maternal Death During or After Pregnancy Linked to Higher Risk of Infant Mortality and Hospitalization

September 26, 2025
blank
Medicine

Volumetric Analysis Reveals Quantitative Impact of Hyaluronic Acid Filler Injections

September 26, 2025
blank
Medicine

Inflammation Drives Senescent Glia in MS Organoids

September 26, 2025
blank
Medicine

Using BMI Change to Assess Anorexia Recovery

September 26, 2025
blank
Medicine

Streamlining Injury Risk Prediction with AI Tools

September 26, 2025
Next Post
UNSW Professor Tim Schmidt in the lab

Fresh light on the path to net zero

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27559 shares
    Share 11020 Tweet 6888
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    968 shares
    Share 387 Tweet 242
  • Bee body mass, pathogens and local climate influence heat tolerance

    645 shares
    Share 258 Tweet 161
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    512 shares
    Share 205 Tweet 128
  • Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function

    466 shares
    Share 186 Tweet 117
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Future Shifts in European Severe Hailstorms and Thunderstorms
  • Addressing Racial and Ethnic Disparities in Occupational Health
  • ASTRO 2025: SBRT Matches Surgery in Effectiveness for Early-Stage Lung Cancer After 10 Years
  • Jingyuan Xu of KIT Honored with “For Women in Science” Sponsorship Award

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,185 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading